Scientists led by Dr. Timo Müller from Helmholtz Munich and the German Center for Diabetes Research (DZD) have now discovered that glucose-dependent insulinotropic polypeptide (GIP) decreases body ...
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from ...
The increasing amount of patients with obesity and type 2 diabetes benefit greatly from the recently developed GIPR:GLP-1R co-agonists. These novel compounds lead to substantial weight loss, offering ...
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones. Tirzepatide incorporates GIP, thus enhancing the insulinotropic effect that may provide ...
Much excitement has built in recent years on the new class of incretin drugs that include glucagon-like-peptide-1 inhibitor (single agonists such as semaglutide) and also dual glucose-dependent ...
Incregen Therapeutics LLC has advanced INC-118, a glucose-dependent insulinotropic polypeptide (GIP) ligand antagonist designed to address long-term obesity management, into IND-enabling studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results